Clinical Trial

A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The objective of this study is to assess the safety, efficacy, and pharmacokinetics of MRG002, as well as the immunogenicity as defined by the incidence of anti-drug antibody (ADA) of MRG002 in patients with HER2-positive advanced solid tumors and locally advanced or metastatic gastric/gastroesophageal junction (GEJ) cancer.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2020-07-27; most recent amendment 2024-10-18.
Status change: Recruiting → Active, Not Recruiting 2024-10-18
Trial Details
NCT Number NCT04492488
Lead Sponsor Shanghai Miracogen Inc.
Conditions Advanced Solid Tumors, Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Cancer
Enrollment 129 participants
Start Date 2021-05-24
Primary Completion 2022-10-18 (estimated)
Study Completion 2024-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-10-22